Camille Carroll

Professor Camille Carroll is a leading academic at Newcastle University, specializing in neurology and clinical research. Her work focuses on Parkinson's disease, with a particular emphasis on disease-modifying therapies, digital health solutions, and improving clinical trial methodologies. She has contributed to major studies evaluating treatments like exenatide and opicapone, and pioneered initiatives to enhance patient engagement in research through platforms such as federated learning approaches and self-management interventions. Her research spans genetic epidemiology, comorbidity management, and the integration of artificial intelligence in healthcare.

Professor Carroll's academic contributions include over 50 peer-reviewed publications since 2021, addressing topics such as drug prioritization, biomarker identification, and trial design innovation. She collaborates internationally, leading multi-center trials and co-chairing initiatives like the Global Parkinson’s Genetics Program. Her work emphasizes translational research, bridging basic science discoveries with clinical application to improve patient outcomes.

Key projects include the Exenatide-PD3 trial examining potential neuroprotective effects, the PD STAT study evaluating digital health technologies, and the ADepT-PD trial investigating antidepressants in Parkinson’s. She has also developed peer-led interventions such as the 'First Steps' program to empower newly diagnosed patients. Her expertise in genomic analysis has advanced understanding of Parkinson’s risk loci across diverse populations.

Professor Carroll advocates for inclusive research practices, ensuring under-served populations are represented in clinical studies. Her lab integrates genetic, clinical, and digital health data to accelerate drug development, while maintaining a focus on patient-centric outcomes through novel trial designs and outcome measures.